FDA Issues Warning to Biotech Billionaire Over Misleading Cancer Drug Claims
Regulatory Action Against Unsubstantiated Medical Claims
The Food and Drug Administration took decisive action this week against prominent biotech entrepreneur Dr. Patrick Soon-Shiong, issuing a formal warning letter regarding misleading statements about his company’s bladder cancer medication. The federal health agency expressed serious concerns about claims made by Soon-Shiong suggesting that Anktiva, manufactured by his company ImmunityBio Inc., could potentially treat, cure, or even prevent various types of cancer beyond its approved use. This regulatory intervention highlights the ongoing tension between pharmaceutical innovation and the strict marketing regulations designed to protect patients from false or exaggerated medical claims. The billionaire businessman, who also owns the Los Angeles Times and has built an empire through various biotech acquisitions, made these controversial statements during a podcast appearance that has since raised red flags with federal regulators. The immediate market reaction was severe, with ImmunityBio’s stock plummeting more than 24% in Tuesday trading as investors absorbed the news of the FDA’s enforcement action, demonstrating how regulatory warnings can have significant financial consequences for pharmaceutical companies.
The Controversial Podcast Appearance and Specific Claims
The problematic statements at the heart of the FDA’s concern were made during a January episode of The Sean Spicer Show podcast, which bore the provocative title “Is the FDA blocking life-saving cancer treatments?” During this interview, Soon-Shiong, who serves as both executive chairman and chief medical officer of ImmunityBio, made several sweeping claims about his company’s drug that extended far beyond what scientific evidence and FDA approval actually support. He characterized the medication as “the most important molecule that could cure cancer,” a statement that represents exactly the kind of overreach that concerns federal health regulators. Perhaps even more concerning, Soon-Shiong told listeners that while Anktiva has received official approval only for bladder cancer treatment, “it actually can treat all cancers.” Later in the same episode, he expanded his claims even further, suggesting that the therapy could prevent cancer in individuals who had been exposed to radiation. These statements collectively paint a picture of a miracle drug with capabilities that extend across the entire spectrum of cancer treatment and prevention, claims that the FDA found to be misleading and potentially dangerous to patients seeking cancer treatment options.
Understanding What Anktiva Actually Does
To understand why the FDA took such strong action, it’s important to know what Anktiva is actually approved to do. The medication received FDA approval in 2024, but only for a very specific and limited use: treating patients with a particularly difficult-to-treat form of bladder cancer. This targeted approval came after the drug demonstrated effectiveness for this specific patient population in clinical trials. ImmunityBio has been actively working to expand the drug’s approved uses, conducting research and seeking FDA approval for additional applications, including certain forms of lung cancer and pancreatic cancer. However, these expanded uses have not yet received regulatory approval, meaning the company cannot legally market the drug for these purposes. The process of gaining FDA approval for new drug applications is rigorous and time-consuming, requiring substantial clinical evidence demonstrating both safety and effectiveness for each specific condition. The regulatory system is designed this way deliberately, to ensure that patients and doctors have reliable, scientifically validated information about what treatments actually work for which conditions, rather than relying on hopeful speculation or preliminary research findings.
The FDA’s Specific Concerns and Legal Violations
The warning letter from the FDA, formally addressed to ImmunityBio CEO Richard Adcock, outlined several specific violations of federal drug marketing regulations. Regulators stated that Soon-Shiong’s statements “create a misleading impression” about what the drug can actually accomplish, potentially leading patients and healthcare providers to have unrealistic expectations about treatment outcomes. Additionally, the FDA took issue with the fact that the podcast episode contained no information whatsoever about the risks and potential side effects associated with Anktiva. Federal law requires that any promotional material for prescription drugs must provide balanced information, presenting both potential benefits and known risks in a fair manner. Anktiva, like virtually all medications, does carry risks, including urinary tract infections, pain, chills, and pyrexia (fever). Patients and doctors need access to this complete picture to make informed decisions about treatment options. The FDA also raised similar concerns about a television advertisement for Anktiva, noting that both the TV ad and the podcast inappropriately referred to the medication as a “cancer vaccine,” which regulators stated is simply false and misleading to the public.
Company Response and Compliance Timeline
Following the FDA’s action, ImmunityBio moved quickly to demonstrate cooperation with federal regulators. By Tuesday afternoon, the link to the controversial podcast episode had been removed from the company’s website, indicating an immediate effort to limit further exposure to the problematic content. Sarah Singleton, a spokesperson for the Culver City, California-based biotech firm, provided a statement acknowledging the seriousness of the situation. She indicated that ImmunityBio takes the FDA’s warning “very seriously” and committed to “work cooperatively with the agency to address the matters raised in the letter.” The FDA has given the company a 15-day deadline to correct the identified problems and respond in writing with a detailed plan for how they intend to address the regulatory concerns. This relatively short timeframe underscores the urgency with which the FDA views these violations. Such warning letters are part of the FDA’s enforcement toolkit, serving as formal notice that a company has violated regulations and must take corrective action. If companies fail to adequately respond or continue making misleading claims, they can face escalating consequences, including financial penalties, restrictions on marketing activities, or in extreme cases, actions affecting their ability to sell the drug altogether.
Broader Context and Implications for the Industry
This enforcement action against ImmunityBio represents part of a broader pattern of increased regulatory vigilance under the current FDA administration. The agency has been stepping up warnings not only against pharmaceutical manufacturers but also against online pharmacies, with particular attention to statements made by company executives during television appearances and podcast interviews. This expanded scope of enforcement reflects the changing media landscape, where company leaders increasingly bypass traditional advertising channels to communicate directly with potential patients and investors through new media platforms. The FDA’s action sends a clear message that regulatory requirements apply regardless of the medium used to communicate about drugs, whether through formal advertisements, social media, podcasts, or any other platform. For the pharmaceutical industry more broadly, this case serves as a reminder that company executives must exercise extreme caution when discussing their products publicly, ensuring that all statements align with FDA-approved labeling and are supported by adequate scientific evidence. The substantial stock price decline following the warning also demonstrates that investors are highly sensitive to regulatory risk, understanding that FDA enforcement actions can have serious consequences for a company’s reputation, market access, and ultimate commercial success. As cancer remains one of the most feared diagnoses and a leading cause of death, the potential for misleading claims to influence desperate patients and their families makes accurate, honest communication about cancer treatments particularly important from both ethical and regulatory perspectives.
